This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sanofi-Aventis Revenue Swells

Sanofi-Aventis (SNY) said Monday that full-year sales rose 9% to $33 billion as strong gains from its vaccine business and several signature products were partly offset by generic competition for several other drugs.

Fourth-quarter sales gained 5% to $8.46 billion.

The French company won't issue its earnings results until Feb. 24, although it said last year's earnings per share, excluding one-time items, should be about 25% higher than for 2004.

Meanwhile, many analysts are paying more attention to two big upcoming events that will have a major impact during the rest of the decade than to last year's and last quarter's sales and earnings.

Next month, the Food and Drug Administration is supposed to rule on Acomplia, a proposed treatment for obesity and addiction to smoking that has made some analysts giddy with excitement.

In April, Sanofi-Aventis will ask a U.S. court to prevent another company from selling a cheap, generic copy of the anticoagulant Plavix, the company's second-biggest product and the biggest-selling drug for its marketing partner Bristol-Myers Squibb (BMY).

"Each event has the ability to impact shares significantly," says Tim Anderson, of Prudential Equity Group, in a research report issued last week.

A court defeat for the generic challenger means five more years of patent protection for a drug that produced $2.45 billion of sales for Sanofi-Aventis and $3.82 billion for Bristol-Myers Squibb. The FDA recently allowed the Canadian company Apotex to sell generic Plavix, but Anderson and other analysts doubt Apotex will act until the court has ruled, or unless it settles with Sanofi-Aventis.

A favorable FDA decision for Acomplia means the drug could be on the market during the second quarter. "Acomplia is the most promising late-stage pipeline product" among European drug companies, says Gbola Amusa, of Sanford C. Bernstein, in a research report published several days before Sanofi-Aventis issued in earnings report. "The weight is over."

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.37 +154.57 0.87%
S&P 500 2,077.97 +7.32 0.35%
NASDAQ 4,778.7890 +13.4090 0.28%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs